NVS 241220 85.00C (NVS241220C85000) Stock Options, News & Quotes

US OptionsDetailed Quotes

NVS241220C85000

Watchlist

0.00
0.000.00%

15min DelayTrading Dec 19 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Benzinga4minutes ago
Sanofi: Kress Was the CEO of MorphoSys From 2019 Until It Was Acquired by Novartis in 2024
Dow Jones12:06 ET
Market Chatter: Novartis to Close MorphoSys Sites, Affecting 330 Jobs
MT NewswiresDec 19 07:47 ET
Novartis AG (NOVN) Gets a Sell From Barclays
TipRanksDec 19 05:45 ET · Ratings
The prospects of European Medical Care stocks are complex, with USA policies and new drug trial results being the key factors.
After falling from a high position in the last few months of 2024, European Medical Care stocks face the risks of US politics and the results of high-risk new drug trials in the new year.
Zhitong FinanceDec 19 01:48 ET
Top Gap Ups and Downs on Wednesday: CI, IBN, EA and More
Moomoo NewsDec 18 18:00 ET · Markets

Comments

Stock_Drift

7 hours ago

$BioAge Labs (BIOA.US)$ $Novartis AG (NVS.US)$

BioAge and Novartis seek drug targets for ageing-related diseases

10xStockPicks

Dec 15 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

Asherboy88

Dec 11 08:09

$Novartis AG (NVS.US)$ what is happening ?? keeps going down